论文部分内容阅读
许多因素所致的肝脏疾病都有可能发展为终末期肝病,而终末期肝病目前唯一有效的治疗方法就是原位肝移植。然而,由于受供体肝脏短缺等因素的限制,细胞治疗方法一直被临床上所期待。近年来,基于谱系重编程的诱导型肝干细胞和诱导型肝实质细胞的技术体系的出现,为解决肝脏疾病细胞治疗中细胞来源匮乏的问题提供了新的思路,也加速了肝脏疾病细胞治疗研究向临床转化的进程。该文介绍了肝脏疾病细胞治疗研究中供体细胞来源的现状,并重点介绍了谱系重编程获取肝系细胞的研究进展。
Many factors of liver disease are likely to develop into end-stage liver disease, and the only effective treatment of end-stage liver disease is orthotopic liver transplantation. However, due to the donor liver shortage and other factors, cell therapy has been clinically expected. In recent years, the emergence of technical systems based on pedigree reprogramming of induced hepatic stem cells and induced hepatic parenchymal cells has provided a new way of thinking to solve the problem of lack of cell sources in the treatment of liver disease cells, and accelerated the research of liver disease cell therapy The process of clinical transformation. This article describes the current status of donor cell sources in the treatment of liver disease cells and highlights the progress made in the reprogramming of liver cells by lineage reprogramming.